July 31, 2008
AtriCure to Present at the BMO Focus on Healthcare and Canaccord Adams Global Growth Conferences in August
WEST CHESTER, Ohio, July 31 /PRNewswire-FirstCall/ -- AtriCure, Inc. , a medical device company and a leader in cardiac surgical ablation systems, today announced that it will present at the following investor conferences during August:
-- The BMO Focus on Healthcare Conference, Wednesday, August 6, 2008 at the Millennium Broadway Hotel in New York. David J. Drachman, President and Chief Executive Officer, is scheduled to present at 9:00 a.m. Eastern time. -- The Canaccord Adams Global Growth Conference, Wednesday, August 13, 2008 at the Intercontinental Hotel in Boston. Mr. Drachman is scheduled to present at 10:30 a.m. Eastern time.
Both presentations will be available for replay for 30 days following the presentations at http://www.atricure.com/Investor_RelationsAbout AtriCure, Inc.
AtriCure, Inc. is a medical device company and a leader in developing, manufacturing and selling innovative cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac, or heart, tissue. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure Isolator(R) bipolar ablation system as a treatment alternative during open-heart surgical procedures to create lesions in cardiac tissue to block the abnormal electrical impulses that cause atrial fibrillation, or AF, a rapid, irregular quivering of the upper chambers of the heart. Additionally, medical journals and leading cardiothoracic surgeons have described the AtriCure Isolator(R) system as a promising treatment alternative for patients who may be candidates for sole-therapy minimally invasive procedures. AF affects more than 5.5 million people worldwide and predisposes them to a five-fold increased risk of stroke.
The FDA has cleared the AtriCure Isolator(R) system, including its Isolator Synergy(TM) ablation clamps, and AtriCure's multifunctional pen and Coolrail(TM) linear ablation device, for the ablation, or destruction, of cardiac tissue during surgical procedures. Additionally, the FDA has cleared AtriCure's multifunctional pen for temporary pacing, sensing, stimulating and recording during the evaluation of cardiac arrhythmias. To date, the FDA has not cleared or approved AtriCure's products for the treatment of AF. AtriCure's left atrial appendage clip system has not been approved for commercial use.
Contact: AtriCure, Inc. Julie A. Piton Vice President and Chief Financial Officer (513) 755-4561 firstname.lastname@example.org
CONTACT: Julie A. Piton of AtriCure, Inc., Vice President and ChiefFinancial Officer, +1-513-755-4561, email@example.com
Web site: http://www.atricure.com/